Klaria annual report 2025 shows net sales of 9.0 MSEK
R&D costs were 28.3 MSEK, loss after tax was -47.1 MSEK, and cash was 0.3 MSEK at year-end.
See the latest news and media coverage for Klaria. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of transmucosal alginate film drugs
klaria.comLast updated
In short: Klaria secured a 25 MSEK bridge loan, reported a -47.1 MSEK loss for 2025, and licensed its migraine film to CNX Therapeutics.
R&D costs were 28.3 MSEK, loss after tax was -47.1 MSEK, and cash was 0.3 MSEK at year-end.
The agreement includes an option for an additional 15 MSEK (total 40 MSEK), supports global market access efforts, disburses immediately and runs until 2027-05-27.
The report shows net sales of 0.1 MSEK, R&D expenses of 4.9 MSEK, and a loss after tax of -8.7 MSEK.
The meeting will be held in Stockholm and deals with election of board and authorization for new share issue.
The lending app is accused of targeting vulnerable borrowers with non-underwritten loans and predatory autopay.
Get access to full transcripts of current and past earnings calls to further evaluate Klaria Pharma Holding AB (KLAR:XSTO) stock's performance and strategic direction...
- Net sales 0.0 MSEK (0.0 MSEK) - Other income 0.0 MSEK (0.0 MSEK) - R&D expenses for the quarter amounted to 4.8 MSEK (9.3...
Klaria Pharma's board has decided on a rights issue that needs to be voted through at an extraordinary general meeting on June 16. Photo: Klaria Pharma Holding Klaria Pharma...
Track Klaria and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.